$PLRX

Pliant Therapeutics (Nasdaq: PLRX) announced a presentation at ESMO Congress 2026 about its Phase 1b FORTIFY trial of PLN-101095 for ICI-refractory solid tumors. The trial is enrolling patients with NSCLC, high tumor mutational burden, or clear cell renal cell carcinoma. PLN-101095 is a dual-selective inhibitor of αvß8 and αvß1 integrins, being tested in combination with pembrolizumab.

Pliant Therapeutics (PLRX) shares rose about 6% premarket after the FDA granted Fast Track designation to PLN-101095, an oral dual integrin inhibitor, to be used with pembrolizumab for solid tumors resistant to immune checkpoint inhibitors. PLN-101095 is in the Phase 1a/1b FORTIFY trial. The company reported about $159.6M cash to fund operations into H2 2028.

PLIANT THERAPEUTICS, INC. (PLRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. a

PLIANT THERAPEUTICS, INC. (PLRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. plrx-20260709 0001746473 FALSE 0001746473 2026-07-09 2026-07-09 0001746473 plrx:CommonStockParValue0.0001PerShareMember 2026-07-09 2026-07-09 0001746473 plrx:SeriesAJuniorParticipatingPreferredPurchaseRightsMember 2026-07-09 2026-07-09 UNITED STATES SECURITIES AND EXCHANGE COMMIS

Pliant Therapeutics (Nasdaq: PLRX) said it appointed Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to its board. The company cited their oncology drug development and regulatory experience. Pliant is developing PLN-101095 for ICI-refractory advanced or metastatic solid tumors, including a Phase 1b expansion trial (FORTIFY).

Pliant Therapeutics (NASDAQ: PLRX) significantly reduced its net loss to $20.0 million in Q1 2026 from $56.2 million in Q1 2025, primarily due to restructuring efforts and a pivot to oncology. The company maintains a strong cash position of $172.4 million, which is expected to fund operations for at least the next 12 months. Pliant is advancing its lead oncology program, PLN-101095, with a Phase 1b trial underway and updated Phase 1 data showing anti-tumor activity.

Pliant Therapeutics (PLRX) has launched a new $50 million "at-the-market" equity program with Leerink Partners, allowing the company to sell common stock to raise capital. This new program replaces a prior 2021 agreement with Cantor Fitzgerald & Co., which was terminated without penalty and with no shares sold. An analyst rating on PLRX stock is currently Hold with a $1.00 price target, and TipRanks' AI Analyst, Spark, rates the stock as Neutral due to weak financial performance despite some short-term momentum.

Pliant Therapeutics (NASDAQ: PLRX) is set to release Phase I clinical trial data for its solid tumor drug candidate, Pln-101095, at the 2026 American Association for Cancer Research (AACR) Annual Meeting. This disclosure will detail the drug's safety, tolerability, and preliminary efficacy in advanced solid tumor patients, particularly those with liver or pancreatic cancer. Positive early data could act as a catalyst for the biotech company's stock, though investors should monitor subsequent clinical progress.

Pliant Therapeutics, Inc. (NASDAQ:PLRX) experienced a significant 20.3% drop in short interest in December, with the total short interest falling to 3,182,879 shares. The short-interest ratio for PLRX is currently 1.2 days, and institutional investors own a substantial 97.3% of the stock. Despite a recent trading increase and some analyst upgrades, the stock's average rating remains "Reduce" with an average price target of $3.93.

Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025